TOPLINE:

In a phase 3 trial, toripalimab-based chemotherapy with radiotherapy without concurrent cisplatin achieved noninferior 3-year failure-free survival compared with standard therapy in patients with locoregionally advanced nasopharyngeal carcinoma. The less intense treatment regimen also led to fewer incidences of vomiting, supporting the feasibility of omitting concurrent cisplatin.

METHODOLOGY:

Cisplatin-based chemoradiotherapy is the standard treatment for nasopharyngeal carcinoma, but toxicity is high. The PD-1 blockade toripalimab improves survival but further increases adverse effects. Past studies showed that adding concurrent cisplatin to radiotherapy significantly increases the incidence of severe nausea, vomiting, and anorexia in patients with this kind of cancer.

Resea

See Full Page